As filed with the Securities and Exchange Commission on May 24, 2024.
Registration No. 333-153734
Registration No. 333-228747
Registration No. 333-237580
Registration No. 333-261025
_____________________________________________________________________________________________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________________________________

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-153734
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-228747
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237580
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-261025
UNDER THE SECURITIES ACT OF 1933
______________________________________________
INOTIV, INC.
(Exact name of registrant as specified in its charter)

Indiana
(State or other jurisdiction of incorporation or organization)
35-1345024
(I.R.S. Employer Identification No.)
2701 Kent Avenue
West Lafayette, Indiana 47906-1382
(Address of Principal Executive Offices) (Zip Code)

Inotiv, Inc. 2024 Equity Incentive Plan
Amended and Restated Inotiv, Inc. 2018 Equity Incentive Plan
(Full title of the plan)

Beth A. Taylor
Chief Financial Officer
Inotiv, Inc.
2701 Kent Avenue
West Lafayette, Indiana 47906-1382
(765) 463-4527
(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copy to:
Christine G. Long
Griffin D. Foster
Faegre Drinker Biddle & Reath LLP
600 E. 96th Street, Suite 600
Indianapolis, Indiana 46240
(317) 569-9600

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o Non-accelerated filer o
Accelerated filer x Smaller Reporting Company x Emerging growth company o




If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
______________________________________________________________________

EXPLANATORY NOTE

Inotiv, Inc. (the “Company”) has previously filed with the Securities and Exchange Commission (the “Commission”) certain Registration Statements on Form S-8, to register its common shares, no par value per share, and paid related registration fees, as follows:

•
Registration Statement No. 333-153734, filed September 30, 2008, registering 500,000 shares under the Bioanalytical Systems, Inc. 2008 Stock Option Plan (the “2008 Plan”), with a registration fee of $135.00;
•
Registration Statement No. 333-228747, filed December 11, 2018, registering 700,000 shares under the 2008 Stock Option Plan as Amended and Restated in the form of the Amended and Restated Bioanalytical Systems, Inc. 2018 Equity Incentive Plan (the “Prior 2018 Plan”), with a registration fee of $112.84;
•
Registration Statement No. 333-237580, filed April 6, 2020, registering 700,000 shares under the Prior 2018 Plan, with a registration fee of $300.75; and
•
Registration Statement No. 333-261025, filed November 12, 2021, registering 1,500,000 shares under the Amended and Restated Inotiv, Inc. 2018 Equity Incentive Plan (the “2018 Plan”), with a registration fee of $7,172.00.
Such Registration Statements are referred to herein as the “Registration Statements.” The Prior 2018 Plan amended and restated the 2008 Plan, after which the Prior 2018 Plan was further amended and renamed the 2018 Plan; references below to the 2018 Plan refer to the 2018 Plan as including the Prior 2018 Plan and all amendments and restatements.

The shareholders of the Company approved the Company’s 2024 Equity Incentive Plan (the “2024 Plan”) on March 14, 2024 (the “Approval Date”). The total number of common shares for which awards may be granted under the 2024 Plan, includes, in addition to 1,500,000 new shares (registered concurrently on a new Registration Statement on Form S-8): (a) 180,172 shares remaining available for future grants under the 2018 Plan as of the Approval Date; and (b) up to 2,158,156 common shares subject to awards that were outstanding under the 2018 Plan on the Approval Date that expire, are forfeited or canceled, or are settled for cash or exchanged ((a) and (b) together, the “Carryover Shares”). The Company’s authority to grant new awards under the 2018 Plan terminated upon shareholder approval of the 2024 Plan on the Approval Date.

Accordingly, pursuant to the undertaking in Item 512(a)(1)(iii) of Regulation S-K that the Company disclose a material change in the plan of distribution as it was originally disclosed in the Registration Statements, the Company is filing this Post-Effective Amendment No. 1 to the Registration Statements to reflect that, as of the Approval Date, the Carryover Shares may be issued under the 2024 Plan and to file as an exhibit hereto a copy of the 2024 Plan. This Post-Effective Amendment No. 1 to the Registration Statements amends and supplements the items listed below. All other items of the Registration Statements are incorporated herein by reference without change.

PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The information specified in Part I of Form S-8 is not required to be filed with the Commission either as part of this registration statement or as prospectuses or prospectus supplements pursuant to the introductory Note to Part I of Form S-8 and Rule 424 under the Securities Act of 1933, as amended (the “Securities Act”). The information required in the Section 10(a) prospectus is included in the documents being maintained and delivered by the Company as required by Part I of Form S-8 and by Rule 428 under the Securities Act.


PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT



Item 3. Incorporation of Documents by Reference.

This Company incorporates by reference in this registration statement the documents and reports listed below (other than portions of these documents that are deemed to have been furnished and not filed):

●
the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023, filed with the Commission on February 7, 2024, and the Company’s Quarterly Report on Form 10-Q/A for the fiscal quarter ended March 31, 2024, filed with the Commission on May 16, 2024;
●
the Company’s Current Reports on Form 8-K (in all cases other than information furnished rather than filed pursuant to any Form 8-K or 8-K/A) filed with the Commission on October 19, 2023 and March 19, 2024; and
●
the description of the Company’s common shares set forth in its registration statement on Form 8-A12G filed on November 12, 1997, as updated by any and all amendments and reports filed for the purpose of updating that description.
All reports and other documents filed by the Company pursuant to Section 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended, subsequent to the date of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents. Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Company under Items 2.02 or 7.01 of any Current Report on Form 8-K or any other information that the Company may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this registration statement. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement or any accompanying prospectus

Item 4. Description of Securities.

Not Applicable.

Item 5. Interests of Named Experts and Counsel.

Not Applicable.


Item 6. Indemnification of Directors and Officers.

Chapter 37 of the Indiana Business Corporation Law (as amended from time to time, the “IBCL”) authorizes every Indiana corporation to indemnify its officers and directors under certain circumstances against liability incurred in connection with proceedings to which the officers or directors are made a party by reason of their relationship to the corporation. Officers and directors may be indemnified where they have acted in good faith, which means, in the case of official action, they reasonably believed the conduct was in the corporation’s best interests, and in all other cases, they reasonably believed the conduct was at least not opposed to the best interests of the corporation, and in the case of criminal proceedings they had reasonable cause to believe the conduct was lawful or there was no reasonable cause to believe the conduct was unlawful. Chapter 37 also requires every Indiana corporation to


indemnify any of its officers or directors (unless limited by the articles of incorporation of the corporation) who were wholly successful, on the merits or otherwise, in the defense of any such proceeding against reasonable expenses incurred in connection with the proceeding. A corporation may also, under certain circumstances, pay for or reimburse the reasonable expenses incurred by an officer or director who is a party to a proceeding in advance of final disposition of the proceeding. Chapter 37 states that the indemnification provided for therein is not exclusive of any other rights to which a person may be entitled under the articles of incorporation, bylaws or resolutions of the board of directors or shareholders.

The Company's second amended and restated articles of incorporation and second amended and restated bylaws provide for indemnification, to the fullest extent permitted by the IBCL, of its directors, officers and employees against liability and reasonable expenses that may be incurred by them in connection with proceedings in which they are made a party by reason of their relationship to the Company.

The Company maintains directors’ and officers’ liability insurance policies, which insure against liabilities that directors or officers may incur in such capacities. These insurance policies may be sufficiently broad to permit indemnification of the Company’s directors and officers for liabilities, including reimbursement of expenses incurred, arising under the securities laws or otherwise.

Item 7. Exemption from Registration Claimed.

Not Applicable.

Item 8. Exhibits
Exhibit Number
Description
4.1
4.2
4.3
4.4
5.1*
5.2
5.3
5.4
5.5
23.1*
23.2*
23.3
23.4
23.5


23.6
24.1*
Powers of Attorney (contained in the signature pages to this registration statement)
__________________
* Filed herewith

Item 9. Undertakings.

(a) The Company hereby undertakes:

(1)    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i)    To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii)    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee” table in the effective registration statement; and

(iii)    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement;

(2)    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

(3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b)    The Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c)    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.



SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of West Lafayette, Indiana, on the 24th day of May, 2024.

INOTIV, INC.
By:
/s/ Beth A. Taylor
Beth A. Taylor
Chief Financial Officer and Senior Vice President - Finance

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints Robert Leasure, Jr. and Beth A. Taylor, and each of them, each with full power to act without the other, his/her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution for him/her and in his/her name, place and stead, in any and all capacities, to sign any or all amendments to this registration statement, and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto each of said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he/she might or could do in person hereby ratifying and confirming that each of said attorneys-in-fact and agents or his/her substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

SignatureCapacityDate
/s/ Robert W. Leasure, Jr.President, Chief Executive Officer and DirectorMay 24, 2024
Robert W. Leasure, Jr.(Principal Executive Officer)
/s/ Beth A. TaylorChief Financial Officer and Senior Vice President - FinanceMay 24, 2024
Beth A. Taylor(Principal Financial Officer)
/s/ Brennan FreemanVice President of Finance and Corporate ControllerMay 24, 2024
Brennan Freeman(Principal Accounting Officer)
/s/ R. Matthew NeffDirectorMay 24, 2024
R. Matthew Neff
/s/ David LandmanDirectorMay 24, 2024
David Landman
/s/ Terry CoelhoDirectorMay 24, 2024
Terry Coelho
/s/ Michael J. HarringtonDirectorMay 24, 2024
Michael J. Harrington
/s/ Nigel BrownDirectorMay 24, 2024
Nigel Brown, Ph.D.
/s/ John E. SagartzDirectorMay 24, 2024
John E. Sagartz, DVM, Ph.D., DAVP


Exhibit 5.1

colorpmsuncoatedstackedeps.jpg
faegrelogo-urlonlyxcopy.jpg
Faegre Drinker Biddle & Reath LLP
600 E. 96th Street, Suite 600
Indianapolis, Indiana 46240
+1 317 569 9600 main

May 24, 2024
Board of Directors
Inotiv, Inc.
2701 Kent Avenue
West Lafayette, Indiana 47906

Ladies and Gentlemen:

We have acted as counsel to Inotiv, Inc., an Indiana corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) of the Post-Effective Amendment No. 1 (the “Amendment”) to each of the Company’s: Registration Statement on Form S-8 filed with the Commission on September 30, 2008 (Registration No. 333-153734) (the “2008 Registration Statement”), Registration Statement on Form S-8 filed with the Commission on December 11, 2018 (Registration No. 333-228747) (the “2018 Registration Statement”), Registration Statement on Form S-8 filed with the Commission on April 6, 2020 (Registration No. 333-237580) (the “2020 Registration Statement”) and Registration Statement on Form S-8 filed with the Commission on November 12, 2021 (Registration No. 333-261025) (the “2021 Registration Statement” and, together with the 2008 Registration Statement, the 2018 Registration Statement and the 2020 Registration Statement, the “Registration Statements”) under the Securities Act of 1933, as amended (the “Act”).

The 2008 Registration Statement registered 500,000 of the Company’s common shares, no par value per share (the “Common Shares”), reserved for issuance pursuant to the Bioanalytical Systems, Inc. 2008 Stock Option Plan (the “2008 Plan”). The 2018 Registration Statement registered an additional 700,000 of the Company’s Common Shares reserved for issuance pursuant to the 2008 Plan, as amended and restated in the form of the Amended and Restated Bioanalytical Systems, Inc. 2018 Equity Incentive Plan (the “Prior 2018 Plan”). The 2020 Registration Statement registered an additional 700,000 of the Company’s Common Shares reserved for issuance pursuant to the Prior 2018 Plan. The 2021 Registration Statement registered an additional 1,500,000 of the Company’s Common Shares reserved for issuance pursuant to the Prior 2018 Plan, as further amended on November 4, 2021 and renamed the Inotiv, Inc. 2018 Equity Incentive Plan (as amended through November 4, 2021, the “2018 Plan”).

The Amendment reflects that, pursuant to the terms of the Inotiv, Inc. 2024 Equity Incentive Plan (the “2024 Plan”), which was approved by the Company’s shareholders on March 14, 2024 (the “Approval Date”), the number of the Company’s Common Shares for which awards may be granted under the 2024 Plan includes in addition to 1,500,000 new shares (registered concurrently on a new Registration Statement on Form S-8): (a) 180,172 Common Shares remaining available for future grants under the 2018 Plan as of the Approval Date; and (b) up to 2,158,156 Common Shares subject to awards that were outstanding under the 2018 Plan on the Approval Date that expire, are forfeited or canceled, or are settled for cash or exchanged ((a) and (b) together, the “Carryover Shares”). The Company’s authority to grant new awards under the 2018 Plan terminated upon shareholder approval of the 2024 Plan on the Approval Date.

For purposes of this opinion letter, we have examined the 2008 Plan, the Prior 2018 Plan, the 2018 Plan, the 2024 Plan, the Registration Statements, the Amendment, the second amended and restated articles of incorporation of the Company, as currently in effect, the third amended and restated bylaws of the Company, as currently in effect, and


the resolutions of the Company’s board of directors authorizing the issuance of the Carryover Shares. We have also examined a certificate of the Secretary of the Company dated the date hereof (the “Certificate”) and originals, or copies certified or otherwise authenticated to our satisfaction, of such corporate records and other records, agreements, instruments, certificates of public officials and documents as we have deemed necessary as a basis for the opinions hereinafter expressed and have reviewed such matters of law as we have deemed relevant hereto. As to facts material to this opinion letter, we have relied upon certificates, statements or representations of public officials, of officers and representatives of the Company (including the Certificate) and of others, without any independent verification thereof.

In our examination, we have assumed: (i) the legal capacity of all natural persons; (ii) the genuineness of all signatures, including electronic signatures; (iii) the authenticity of all documents submitted to us as originals; (iv) the conformity to original documents of all documents submitted to us as certified, conformed, photostatic or facsimile copies; (v) the authenticity of the originals of such latter documents; (vi) the truth, accuracy and completeness of the information, representations and warranties contained in the agreements, documents, instruments, certificates and records we have reviewed; and (vii) the absence of any undisclosed modifications to the agreements and instruments reviewed by us.

Based upon such examination and review, and subject to the foregoing and the other qualifications, assumptions and limitations set forth herein, it is our opinion that all necessary corporate action on the part of the Company has been taken to authorize the issuance and sale of the Carryover Shares to be issued in accordance with the 2024 Plan and that, when (a) the Carryover Shares have been issued and sold as contemplated in the Amendment and related prospectus and in accordance with the 2024 Plan and any applicable award agreement, and (b) where applicable, the consideration for the Carryover Shares specified in the 2024 Plan and any applicable award agreement has been received by the Company, the Carryover Shares will be validly issued, fully paid and nonassessable.

The foregoing opinions are limited to the laws of the State of Indiana and speak only as of the date the Amendment becomes effective under the Act. We assume no obligation to revise or supplement this opinion thereafter. This opinion is limited to the specific issues addressed herein, and no opinion may be inferred or implied beyond that expressly stated herein.

We hereby consent to the filing of this opinion as an exhibit to the Amendment. In giving such consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.



Very truly yours,
/s/ Faegre Drinker Biddle & Reath LLP
FAEGRE DRINKER BIDDLE & REATH LLP




Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Post-Effective Amendment No. 1 to the Registration Statements (Form S-8 Nos. 333-153734, 333-228747, 333-237580 and 333-261025) pertaining to the Bioanalytical Systems, Inc. 2008 Stock Option Plan, the Amended and Restated Bioanalytical Systems, Inc. 2018 Equity Incentive Plan and the Amended and Restated Inotiv, Inc. 2018 Equity Incentive Plan of our reports dated December 11, 2023, with respect to the consolidated financial statements of Inotiv, Inc. and the effectiveness of internal control over financial reporting of Inotiv, Inc. included in its Annual Report (Form 10-K) for the year ended September 30, 2023, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Indianapolis, IN
May 24, 2024

Inotiv (NASDAQ:NOTV)
過去 株価チャート
から 5 2024 まで 6 2024 Inotivのチャートをもっと見るにはこちらをクリック
Inotiv (NASDAQ:NOTV)
過去 株価チャート
から 6 2023 まで 6 2024 Inotivのチャートをもっと見るにはこちらをクリック